Prospective real-world evaluation of t(11;14) prevalence and disease biology in multiple myeloma: MEDICI study analysis

作者：Andrew Spencer, Maria Gavriatopoulou, Daniel Coriu, Anna Lysén, Norma C. Gutiérrez, Fernando Escalante, Dorotea Fantl, Roman Hájek, Fernanda Salles Seguro, Gurbakhash Kaur, Rosane Bittencourt, Sandra Bašić‐Kinda, Michael P. Chu, Hana Safah, Joaquín Martínez‐López, Edvan de Queiroz Crusoé, Danielle Leão Cordeiro de Farias, Massimo Offidani, Elham Askari, Ömür Gökmen Sevindik, Vladimír Maisnar, Chieh‐Lin Jerry Teng, Olivia Hughes, Rebekah T. Taylor, Kristin Lehn, Feng Dai, Raphaële Thiébaut-Millot, Xiaotong Li, Lauren Murray, Paul Jung, Emily L. Rossi, Sarah Kongpachith, Alexander Nichol, Jeremy A. Ross, Carlos Hader · 发表于：Blood Advances · 年份：2025 · DOI：10.1182/bloodadvances.2025017214 · 被引用次数：3 · 研究领域：Multiple Myeloma Research and Treatments、Peptidase Inhibition and Analysis、Glycosylation and Glycoproteins Research

ABSTRACT: Genetic abnormalities in multiple myeloma (MM) influence treatment outcomes and may inform therapeutic decisions. The most common chromosomal translocation in MM is t(11;14); however, its role in disease progression is not well defined. We report results from MEDICI, a global, minimally invasive, prospective study evaluating t(11;14) status in newly diagnosed MM (NDMM) and relapsed/refractory MM (RRMM). MEDICI enrolled adult patients (≥18 years) with MM with bone marrow (BM) aspirates collected at diagnosis and/or disease relapse. The primary objective was to determine t(11;14) prevalence in patient BM samples using fluorescent in situ hybridization (FISH) with plasma cell enrichment. Samples from 525 patients (NDMM, n = 306; RRMM, n = 219) were analyzed for t(11;14), with 498 patients (95%) having successful BM FISH test. Prevalence of t(11;14) was 22.1% (110/498 patients; 95% confidence interval [CI], 18.5-26.0) in the overall patient population, 18.8% (56/298 patients; 95% CI, 14.5-23.7) in NDMM, and 27.0% (54/200 patients; 95% CI, 21.0-33.7) in RRMM. Patients with t(11;14)-positive MM were evenly distributed across disease stages (stage I, 24.1%; stage II, 20%; stage III, 21.3%); however, higher rates were observed in African American patients (RRMM odds ratio [OR], 7.27, 95% CI, 1.33-39.83; P = .022) and light-chain only disease (NDMM OR, 3.02, 95% CI, 1.33-6.87; P = .008). Chromosome 1q abnormalities occurred more often in the absence of t(11;14); however, hig...